Regeneron Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75886F1075

SecurityREGN / Regeneron Pharmaceuticals, Inc.
InstitutionCommonwealth Equity Services, Llc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Commonwealth Equity Services, Llc closes position in REGN / Regeneron Pharmaceuticals, Inc.

On April 27, 2026 - Commonwealth Equity Services, Llc filed a 13F-HR form disclosing ownership of 0 shares of Regeneron Pharmaceuticals, Inc. (US:REGN) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 16,122 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -16,122 -100.00 0 -100.00
2026-02-12 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 16,122 -12 -0.07 12,444 138,166.67 0.0166
2025-10-22 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 16,134 -1,621 -9.13 9 0.00 0.0118
2025-08-06 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 17,755 -664 -3.60 9 -18.18 0.0123
2025-05-09 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 18,419 405 2.25 12 -8.33 0.0165
2025-02-10 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 18,014 -967 -5.09 13 -36.84 0.0188
2024-10-18 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 18,981 -1,171 -5.81 20 -9.52 0.0302
2024-07-31 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 20,152 780 4.03 21 16.67 0.0335
2024-04-29 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 19,372 526 2.79 19 12.50 0.0310
2024-02-06 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 18,846 508 2.77 17 6.67 0.0303
2023-10-23 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 18,338 -64 -0.35 15 15.38 0.0313
2023-08-10 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 18,402 -2,254 -10.91 13 -18.75 0.0269
2023-05-11 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 20,656 183 0.89 17 14.29 0.0356
2023-02-07 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 20,473 3,600 21.34 15 -99.88 0.0355
2022-11-14 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 16,873 -820 -4.63 11,623 11.14 0.0300
2022-07-19 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 17,693 1,551 9.61 10,458 -7.23 0.0273
2022-05-04 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 16,142 -6,025 -27.18 11,273 -19.47 0.0258
2022-01-31 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 22,167 -1,867 -7.77 13,999 -3.75 0.0315
2021-10-29 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 24,034 7,628 46.50 14,545 58.74 0.0365
2021-08-11 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 16,406 2,200 15.49 9,163 36.33 0.0233
2021-05-04 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 14,206 2,390 20.23 6,721 17.75 0.0190
2021-02-11 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 11,816 -392 -3.21 5,708 -16.46 0.0172
2020-11-05 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 12,208 -596 -4.65 6,833 -14.43 0.0233
2020-08-12 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 12,804 1,921 17.65 7,985 50.26 0.0301
2020-05-11 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 10,883 1,413 14.92 5,314 49.48 0.0248
2020-02-05 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 9,470 -527 -5.27 3,555 28.20 0.0135
2019-10-30 2019-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 9,997 416 4.34 2,773 -7.51 0.0118
2019-07-19 2019-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 9,581 726 8.20 2,998 -17.55 0.0132
2019-05-13 2019-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,855 -80 -0.90 3,636 8.96 0.0168
2019-02-11 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,935 997 12.56 3,337 4.05 0.0177
2018-11-06 2018-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 7,938 1,481 22.94 3,207 43.94 0.0154
2018-07-31 2018-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,457 771 13.56 2,228 13.79 0.0116
2018-05-14 2018-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 5,686 427 8.12 1,958 -0.96 0.0106
2018-02-12 2017-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 5,259 5,259 1,977 0.0108
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.